GSK (LON:GSK) Share Price Breaks Below Fifty Day Moving Average - Here's Why

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GSK fell below its 50-day moving average on Thursday, trading as low as GBX 1,821 and last at GBX 1,827, below the average of GBX 1,851.56.
  • Analyst sentiment is mixed but leans to Hold: three analysts rate the shares Buy, four Hold and one Sell, with a consensus target price of GBX 2,145.
  • GSK reported quarterly earnings of GBX 54.60 per share and revenue of GBX 888.70 billion; analysts expect full-year EPS of GBX 175.98.
  • Interested in GSK? Here are five stocks we like better.

GSK plc (LON:GSK - Get Free Report) crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of GBX 1,851.56 and traded as low as GBX 1,821. GSK shares last traded at GBX 1,827, with a volume of 5,107,288 shares changing hands.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent analyst reports. Deutsche Bank restated a "hold" rating and set a GBX 2,000 target price on shares of GSK in a report on Tuesday, November 10th. Royal Bank Of Canada started coverage on GSK in a research note on Tuesday, September 8th. They issued a "sector perform" rating and a GBX 1,975 price target for the company. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 price objective on shares of GSK in a research note on Tuesday, October 20th. Finally, Berenberg Bank restated a "buy" rating and issued a GBX 2,200 price target on shares of GSK in a report on Tuesday, November 3rd. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of GBX 2,145.

Read Our Latest Research Report on GSK

GSK Price Performance

The company has a 50 day simple moving average of GBX 1,851.56 and a 200-day simple moving average of GBX 1,952.01. The stock has a market cap of £74.25 billion, a price-to-earnings ratio of 17.32, a P/E/G ratio of 1.24 and a beta of 0.28. The company has a current ratio of 0.86, a quick ratio of 0.73 and a debt-to-equity ratio of 126.38.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share for the quarter. The company had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. Research analysts expect that GSK plc will post 175.98 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Anne Beal purchased 637 shares of the stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the business's stock in a transaction on Friday, September 18th. The shares were acquired at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders have purchased 2,151 shares of company stock valued at $6,021,921 in the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines